Amicus Therapeutics saw its excellent 2012 performance cut in half today, as shares that had been up 70% for the year fell 45% in a single day. The fall came on news that the company's lead drug, called migalastat, which was designed to treat Fabry disease, failed to meet its primary endpoint in its phase 3 trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn break down this news, and discuss where Amicus and GlaxoSmithKline , with whom Amicus was partnered on the compound, can go from here.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Shares of Amicus Cratered Today originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.